日本の糖尿病薬市場レポート：タイプ別、流通チャネル別、地域別、2025年～2033年

日本の糖尿病薬市場の市場規模は2024年に44億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は3.5%で、2033年には59億米ドルに達すると予測しています。血糖値を効果的にコントロールすることを目的とした多種多様な糖尿病薬の開発、製造、販売に携わる製薬企業の数が増加していることが、主に市場成長の原動力となっています。

本レポートで扱う主な質問

• 日本の糖尿病薬市場のこれまでの業績と今後の業績は？
• 日本の糖尿病薬市場へのCOVID-19の影響は？
• 日本の糖尿病薬市場のタイプ別の内訳は？
• 日本の糖尿病薬市場の流通チャネル別の内訳は？
• 日本の糖尿病薬市場のバリューチェーンにはどのような段階がありますか？
• 日本の糖尿病薬の主な促進要因と課題は？
• 日本の糖尿病薬市場の構造と主要プレーヤーは？
• 日本の糖尿病薬市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本の糖尿病薬市場：イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本の糖尿病薬市場情勢

• 過去および現在の市場動向（2019年～2024年）
• 市場予測（2025-2033）

第6章 日本の糖尿病薬市場：タイプ別内訳

• インスリン
• 経口抗糖尿病薬
• 非インスリン注射薬
• 併用薬

第7章 日本の糖尿病薬市場：流通チャネル別内訳

• オンライン薬局
• 病院薬局
• 小売薬局

第8章 日本の糖尿病薬市場：競合情勢

• 概要
• 市場構造
• 市場プレーヤーのポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第9章 主要企業のプロファイル

第10章 日本の糖尿病薬市場：業界分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第11章 付録

Japan diabetes drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 3.5% during 2025-2033. The rising number of established pharmaceutical companies engaged in the development, production, and distribution of a diverse range of diabetes medications, each aiming to control blood glucose levels effectively is primarily driving the market growth.

Diabetes drugs play a pivotal role in managing and treating diabetes, a chronic condition characterized by elevated blood sugar levels due to the body's inability to produce sufficient insulin or utilize it effectively. These pharmaceutical agents are crucial in controlling the progression of the disease and mitigating the risk of complications, such as cardiovascular disease, kidney damage, and vision loss. There are various classes of diabetes drugs, each working differently to regulate blood glucose levels. Some are designed to boost insulin secretion, while others improve insulin sensitivity or decrease the amount of glucose absorbed by the intestines.

Japan Diabetes Drugs Market Trends:

The Japan diabetes drugs market is a rapidly evolving sector, responding to the escalating need stemming from the widespread prevalence of diabetes in the region, predominantly influenced by aging demographics and lifestyle alterations. The dynamics of this market are shaped by the infusion of innovative solutions and relentless research endeavors by prominent pharmaceutical entities, aimed at devising diverse medication strategies to meticulously regulate blood glucose levels. The market is experiencing substantial growth, fueled by a heightened awareness and understanding of diabetes and its associated complications. The propensity towards embracing novel and effective diabetes medications is prominent in Japan, with a significant inclination towards the integration of advanced drugs, such as GLP-1 receptor agonists, which are gaining traction due to their efficacy and multifunctionality in managing blood sugar levels and weight. A distinctive trend in the market is the burgeoning investment in R&D activities, fostering the development of groundbreaking drugs with enhanced capabilities and reduced side effects. The advent of personalized medicine is also playing a pivotal role in shaping the market landscape, enabling more tailored and patient-centric approaches to treatment. The heightened emphasis on healthcare and wellness, coupled with supportive regulatory frameworks and substantial healthcare expenditure, is anticipated to propel the regional market forward over the forecasted period.

Japan Diabetes Drugs Market Segmentation:

Type Insights:

• Insulins
• Basal or Long Acting Insulins
• Lantus (Insulin Glargine)
• Levemir (Insulin Detemir)
• Toujeo (Insulin Glargine)
• Tresiba (Insulin Degludec)
• Basaglar (Insulin Glargine)
• Bolus or Fast Acting Insulins
• NovoRapid/Novolog (Insulin Aspart)
• Humalog (Insulin Lispro)
• Apidra (Insulin Glulisine)
• Traditional Human Insulins
• Novolin/Actrapid/Insulatard
• Humulin
• Insuman
• Biosimilar Insulins
• Insulin Glargine Biosimilars
• Human Insulin Biosimilars
• Oral Anti-diabetic Drugs
• Biguanides
• Metformin
• Alpha-Glucosidase Inhibitors
• Dopamine D2 Receptor Agonist
• Bromocriptin
• SGLT-2 Inhibitor
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Farxiga/Forxiga (Dapagliflozin)
• Suglat (Ipragliflozin)
• DPP-4 Inhibitors
• Onglyza (Saxagliptin)
• Tradjenta (Linagliptin)
• Vipidia/Nesina (Alogliptin)
• Galvus (Vildagliptin)
• Sulfonylureas
• Meglitinides
• Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Victoza (Liraglutide)
• Byetta (Exenatide)
• Bydureon (Exenatide)
• Trulicity (Dulaglutide)
• Lyxumia (Lixisenatide)
• Amylin Analogue
• Symlin (Pramlintide)
• Combination Drugs
• Insulin Combinations
• NovoMix (Biphasic Insulin Aspart)
• Ryzodeg (Insulin Degludec and Insulin Aspart)
• Xultophy (Insulin Degludec and Liraglutide)
• Oral Combination
• Janumet (Sitagliptin and Metformin)

Distribution Channel Insights:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan diabetes drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes drugs market?
• What is the breakup of the Japan diabetes drugs market on the basis of type?
• What is the breakup of the Japan diabetes drugs market on the basis of distribution channel?
• What are the various stages in the value chain of the Japan diabetes drugs market?
• What are the key driving factors and challenges in the Japan diabetes drugs?
• What is the structure of the Japan diabetes drugs market and who are the key players?
• What is the degree of competition in the Japan diabetes drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Diabetes Drugs Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Diabetes Drugs Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Diabetes Drugs Market - Breakup by Type

• 6.1 Insulins
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Segmentation
    • 6.1.3.1 Basal or Long Acting Insulins
      • 6.1.3.1.1 Lantus (Insulin Glargine)
      • 6.1.3.1.2 Levemir (Insulin Detemir)
      • 6.1.3.1.3 Toujeo (Insulin Glargine)
      • 6.1.3.1.4 Tresiba (Insulin Degludec)
      • 6.1.3.1.5 Basaglar (Insulin Glargine)
    • 6.1.3.2 Bolus or Fast Acting Insulins
      • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 6.1.3.2.2 Humalog (Insulin Lispro)
      • 6.1.3.2.3 Apidra (Insulin Glulisine)
    • 6.1.3.3 Traditional Human Insulins
      • 6.1.3.3.1 Novolin/Actrapid/Insulatard
      • 6.1.3.3.2 Humulin
      • 6.1.3.3.3 Insuman
    • 6.1.3.4 Biosimilar Insulins
      • 6.1.3.4.1 Insulin Glargine Biosimilars
      • 6.1.3.4.2 Human Insulin Biosimilars
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 Oral Anti-diabetic Drugs
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Segmentation
    • 6.2.3.1 Biguanides
      • 6.2.3.1.1 Metformin
    • 6.2.3.2 Alpha-Glucosidase Inhibitors
    • 6.2.3.3 Dopamine D2 Receptor Agonist
      • 6.2.3.3.1 Bromocriptin
    • 6.2.3.4 SGLT-2 Inhibitors
      • 6.2.3.4.1 Invokana (Canagliflozin)
      • 6.2.3.4.2 Jardiance (Empagliflozin)
      • 6.2.3.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 6.2.3.4.4 Suglat (Ipragliflozin)
    • 6.2.3.5 DPP-4 Inhibitors
      • 6.2.3.5.1 Onglyza (Saxagliptin)
      • 6.2.3.5.2 Tradjenta (Linagliptin)
      • 6.2.3.5.3 Vipidia/Nesina (Alogliptin)
      • 6.2.3.5.4 Galvus (Vildagliptin)
    • 6.2.3.6 Sulfonylureas
    • 6.2.3.7 Meglitinides
  • 6.2.4 Market Forecast (2025-2033)
• 6.3 Non-Insulin Injectable Drugs
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Segmentation
    • 6.3.3.1 GLP-1 Receptor Agonists
      • 6.3.3.1.1 Victoza (Liraglutide)
      • 6.3.3.1.2 Byetta (Exenatide)
      • 6.3.3.1.3 Bydureon (Exenatide)
      • 6.3.3.1.4 Trulicity (Dulaglutide)
      • 6.3.3.1.5 Lyxumia (Lixisenatide)
    • 6.3.3.2 Amylin Analogue
      • 6.3.3.2.1 Symlin (Pramlintide)
  • 6.3.4 Market Forecast (2025-2033)
• 6.4 Combination Drugs
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.1.2 Market Segmentation
    • 6.3.3.1 Insulin Combinations
      • 6.3.3.1.1 NovoMix (Biphasic Insulin Aspart)
      • 6.3.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 6.3.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
    • 6.3.3.2 Oral Combinations
      • 6.3.3.2.1 Janumet (Sitagliptin and Metformin)
  • 6.4.4 Market Forecast (2025-2033)

7 Japan Diabetes Drugs Market - Breakup by Distribution Channel

• 7.1 Online Pharmacies
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Hospital Pharmacies
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Retail Pharmacies
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)

8 Japan Diabetes Drugs Market - Competitive Landscape

• 8.1 Overview
• 8.2 Market Structure
• 8.3 Market Player Positioning
• 8.4 Top Winning Strategies
• 8.5 Competitive Dashboard
• 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

• 9.1 Company A
  • 9.1.1 Business Overview
  • 9.1.2 Product Portfolio
  • 9.1.3 Business Strategies
  • 9.1.4 SWOT Analysis
  • 9.1.5 Major News and Events
• 9.2 Company B
  • 9.2.1 Business Overview
  • 9.2.2 Product Portfolio
  • 9.2.3 Business Strategies
  • 9.2.4 SWOT Analysis
  • 9.2.5 Major News and Events
• 9.3 Company C
  • 9.3.1 Business Overview
  • 9.3.2 Product Portfolio
  • 9.3.3 Business Strategies
  • 9.3.4 SWOT Analysis
  • 9.3.5 Major News and Events
• 9.4 Company D
  • 9.4.1 Business Overview
  • 9.4.2 Product Portfolio
  • 9.4.3 Business Strategies
  • 9.4.4 SWOT Analysis
  • 9.4.5 Major News and Events
• 9.5 Company E
  • 9.5.1 Business Overview
  • 9.5.2 Product Portfolio
  • 9.5.3 Business Strategies
  • 9.5.4 SWOT Analysis
  • 9.5.5 Major News and Events

10 Japan Diabetes Drugs Market - Industry Analysis

• 10.1 Drivers, Restraints, and Opportunities
  • 10.1.1 Overview
  • 10.1.2 Drivers
  • 10.1.3 Restraints
  • 10.1.4 Opportunities
• 10.2 Porters Five Forces Analysis
  • 10.2.1 Overview
  • 10.2.2 Bargaining Power of Buyers
  • 10.2.3 Bargaining Power of Suppliers
  • 10.2.4 Degree of Competition
  • 10.2.5 Threat of New Entrants
  • 10.2.6 Threat of Substitutes
• 10.3 Value Chain Analysis

11 Appendix